ELOXX PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$247.00K.
- ELOXX PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was -$112.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11 | $0.00 S-1 · filed 2026-09-11 | |
| 2026-03-31 | $0.00 S-1/A · filed 2026-06-04 | ||
| 2025-12-31 | -$359.00K S-1 · filed 2026-09-11 | ||
| 2025-06-30 | -$247.00K derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11 | -$359.00K S-1 · filed 2026-09-11 | |
| 2025-03-31 | -$112.00K S-1/A · filed 2026-06-04 | ||
| 2024-12-31 | $359.00K S-1 · filed 2026-09-11 | ||
| 2023-12-31 | $0.00 S-1 · filed 2026-09-11 | ||
| 2015-12-31 | $0.00 10-Q · filed 2016-02-16 | ||
| 2014-12-31 | $160.78K 10-Q · filed 2016-02-16 | ||
| 2013-12-31 | $0.00 10-Q · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |